Competition to supply free oral anticoagulants

Bayer announced last week it would offer free rivaroxaban (Xarelto) to selected patients under a PFP, while Boehringer Ingelheim (BI) said its first-to-market rival drug dabigatran (Pradaxa), was set to extend its PFP for another three months.

But the National Prescribing Service (NPS) has urged GPs to be cautious in switching to the warfarin alternatives.

“It would be useful if the PFPs were rolled out when we know that the product will be subsidised by the PBS and when we have a time frame for that decision,” NPS